ATE372774T1 - Medikament zur verabreichung von amifostin und verwandten wirkstoffen - Google Patents

Medikament zur verabreichung von amifostin und verwandten wirkstoffen

Info

Publication number
ATE372774T1
ATE372774T1 AT02713473T AT02713473T ATE372774T1 AT E372774 T1 ATE372774 T1 AT E372774T1 AT 02713473 T AT02713473 T AT 02713473T AT 02713473 T AT02713473 T AT 02713473T AT E372774 T1 ATE372774 T1 AT E372774T1
Authority
AT
Austria
Prior art keywords
administration
amifostine
medication
related ingredients
compounds
Prior art date
Application number
AT02713473T
Other languages
English (en)
Inventor
Martin Stogniew
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Application granted granted Critical
Publication of ATE372774T1 publication Critical patent/ATE372774T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02713473T 2001-02-05 2002-02-04 Medikament zur verabreichung von amifostin und verwandten wirkstoffen ATE372774T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/775,540 US6573253B2 (en) 1997-02-12 2001-02-05 Methods for the administration of amifostine and related compounds

Publications (1)

Publication Number Publication Date
ATE372774T1 true ATE372774T1 (de) 2007-09-15

Family

ID=25104730

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713473T ATE372774T1 (de) 2001-02-05 2002-02-04 Medikament zur verabreichung von amifostin und verwandten wirkstoffen

Country Status (9)

Country Link
US (1) US6573253B2 (de)
EP (1) EP1368038B1 (de)
JP (1) JP2005504720A (de)
AT (1) ATE372774T1 (de)
AU (1) AU2002245321B2 (de)
CA (1) CA2437087A1 (de)
DE (1) DE60222383T2 (de)
ES (1) ES2289090T3 (de)
WO (1) WO2002062350A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
KR20030014208A (ko) * 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20040146585A1 (en) * 2002-10-31 2004-07-29 Oregon Health & Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
EP2086673A2 (de) * 2006-11-11 2009-08-12 Uop Llc Selektives hydrierungsverfahren mit katalysatorzusammensetzung mit funktioneller oberfläche
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
EP3011339A4 (de) 2013-06-18 2017-01-25 Aminomedix Inc. Zusammensetzungen und verfahren zur herstellung von nierenschutzmittel mit amifostin und aminosäuren
EP3713534A4 (de) * 2017-11-21 2021-08-25 William Marsh Rice University Selektive ablagerung von zytoprotektionsmittel in strahlungsempfindlichen geweben und deren verwendungen
WO2024211590A1 (en) * 2023-04-04 2024-10-10 Xerient Pharma Ltd. Pharmaceutically active compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
DE3888541T2 (de) 1987-12-22 1994-06-23 U S Bioscience Blue Bell Verbesserung der toxizitätskurven in der chemotherapie.
WO1989007942A1 (en) 1988-02-23 1989-09-08 U.S. Bioscience Method for protection from chemotherapeutic side effects
US5869338A (en) 1992-03-13 1999-02-09 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5488042A (en) 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5567686A (en) 1992-03-13 1996-10-22 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5424471A (en) 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
CA2122342A1 (en) 1992-09-04 1994-03-17 Hironori Kawabata Pharmaceutical composition
DE69526395D1 (de) 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5846958A (en) 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6984619B1 (en) 1999-03-19 2006-01-10 Arch Development Corporation Method for protection against tumor metastasis formation

Also Published As

Publication number Publication date
CA2437087A1 (en) 2002-08-15
EP1368038B1 (de) 2007-09-12
AU2002245321B2 (en) 2007-08-02
DE60222383T2 (de) 2008-06-12
US20020035093A1 (en) 2002-03-21
DE60222383D1 (de) 2007-10-25
WO2002062350A1 (en) 2002-08-15
US6573253B2 (en) 2003-06-03
ES2289090T3 (es) 2008-02-01
JP2005504720A (ja) 2005-02-17
EP1368038A1 (de) 2003-12-10

Similar Documents

Publication Publication Date Title
DK1401853T3 (da) Modulatorer af farmakologiske midler
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2004043341A3 (en) Treatment for hemorrhagic shock
ATE326956T1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
DK1007055T3 (da) Anvendelse af amifostin
GB0020504D0 (en) Therapeutic method
MXPA04001912A (es) Aminobenzofenonas novedosas.
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
IL159770A0 (en) Calcium salts with cytotoxic activity
ATE252903T1 (de) Arzneimittel zur behandlung konvulsivischer zustände
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
EP1374873B8 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties